Table 2 |
|||||||
|
Haplotype distribution in patients with AS and controls |
|||||||
|
Haplotypes rs1264457/rs2074505/rs2074503/rs2269709 |
Random controls |
HLA-B27 controls |
P |
HLA-B27 patients with AS |
p1 |
p2 |
|
|
|
|||||||
|
Non B*2709 (B*2709) n = 135 |
n = 40 |
||||||
|
|
|||||||
|
AAGA |
0.42 |
0.52 |
(0.59)* |
9 × 10-4 |
0.68 |
2 × 10-11 |
3 × 10-4 |
|
GGAG |
0.24 |
0.23 |
(0.16) |
ns |
0.12 |
1 × 10-4 |
0.001 |
|
GGGA |
0.14 |
0.10 |
(0.10) |
ns |
0.05 |
7 × 10-4 |
ns |
|
Others |
0.20 |
0.15 |
(0.15) |
ns |
0.15 |
ns |
ns |
|
|
|||||||
|
in brackets = haplotype frequencies referring to 40 HLA-B*2709 positive subjects which had been enclosed in the statistical analysis; p1 = HLA-B27 positive patients with AS vs random controls; p2 = HLA-B27 positive patients with AS vs the pool of the HLA-B27 positive controls. AS = ankylosing spondylitis. |
|||||||
|
Paladini et al. Arthritis Research & Therapy 2009 11:R171 doi:10.1186/ar2860 |
|||||||